Medtronic PLC (NYSE:MDT) Receives $103.92 Average Price Target from Analysts

Shares of Medtronic PLC (NYSE:MDT) have earned a consensus rating of “Moderate Buy” from the twenty-eight research firms that are presently covering the company, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $103.92.

A number of analysts have issued reports on the company. Rothschild & Co Redburn cut their target price on Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research note on Friday, June 5th. Weiss Ratings raised shares of Medtronic from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, September 4th. Leerink Partners dropped their price objective on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating for the company in a report on Thursday, June 4th. Royal Bank Of Canada restated an “outperform” rating and set a $118.00 price objective on shares of Medtronic in a research report on Wednesday, September 2nd. Finally, Mizuho set a $115.00 target price on shares of Medtronic in a research note on Wednesday, September 2nd.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic reportedly raised its outlook again as demand for heart and cardiovascular devices continued to improve. Analysts also cited market-share gains in electrophysiology and stronger momentum across key franchises, supporting expectations for sustained growth. Medtronic Raises its Outlook Again as Heart Device Demand Keeps Climbing
• Positive Sentiment: The FDA cleared Medtronic’s LigaSure instrument for use with the Hugo robotic-assisted surgery system in the United States. The broader instrument portfolio could help Hugo compete for more procedures and expand Medtronic’s long-term surgical-robotics revenue. Medtronic Wins FDA Clearance for LigaSure Instrument on Hugo Robot
• Positive Sentiment: Needham said Medtronic’s deal with Cornerstone Robotics should complement the Hugo system. The partnership may strengthen Medtronic’s robotics capabilities and accelerate expansion of the platform. Medtronic’s Deal with Cornerstone Robotics to Complement Hugo Surgery System
• Positive Sentiment: Industry forecasts call for the global vascular-access-device market to grow at a 6.7% annual rate through 2031. Medtronic could benefit from rising demand for IV therapies and safer, antimicrobial and ultrasound-guided devices, although the report describes an industry opportunity rather than a company-specific announcement. Vascular Access Device Market Forecast
• Neutral Sentiment: Medtronic launched a share-exchange offer for up to approximately 225.4 million newly issued shares as part of its planned diabetes-business spin-off. The separation could sharpen strategic focus, but investors are weighing dilution, execution risks and the eventual ownership structure. Medtronic Advances Diabetes Spin-Off with Share Exchange
• Negative Sentiment: Executive Vice President Harry Kiil sold 1,483 shares worth about $139,000. The transaction reduced his position by 3.4%, but its relatively small size and his remaining substantial ownership limit the signal.

Insider Activity

In other news, EVP Harry Kiil sold 1,483 shares of Medtronic stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the sale, the executive vice president owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. The trade was a 3.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.27% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Medtronic

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. raised its holdings in Medtronic by 0.7% in the 2nd quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock valued at $8,919,846,000 after buying an additional 838,220 shares during the period. State Street Corp boosted its stake in Medtronic by 2.0% during the fourth quarter. State Street Corp now owns 61,660,158 shares of the medical technology company’s stock worth $5,966,780,000 after buying an additional 1,199,621 shares during the period. JPMorgan Chase & Co. boosted its stake in Medtronic by 2.7% during the fourth quarter. JPMorgan Chase & Co. now owns 53,616,694 shares of the medical technology company’s stock worth $5,150,420,000 after buying an additional 1,419,730 shares during the period. Capital Research Global Investors increased its position in shares of Medtronic by 12.6% during the fourth quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock valued at $3,321,101,000 after acquiring an additional 3,880,174 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Medtronic by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 27,879,481 shares of the medical technology company’s stock valued at $2,665,832,000 after acquiring an additional 231,919 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Stock Down 0.6%

MDT stock opened at $92.19 on Tuesday. The company has a market cap of $117.92 billion, a price-to-earnings ratio of 22.71, a PEG ratio of 2.10 and a beta of 0.56. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. Medtronic has a 12 month low of $73.31 and a 12 month high of $106.33. The firm has a 50-day moving average of $88.92 and a two-hundred day moving average of $85.03.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The business had revenue of $9.76 billion for the quarter, compared to analysts’ expectations of $9.55 billion. During the same period in the previous year, the firm posted $1.26 EPS. The business’s revenue for the quarter was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, analysts forecast that Medtronic will post 5.97 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. Medtronic’s dividend payout ratio is 70.94%.

About Medtronic

Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.